Fig. 5From: A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutationPFS (a) and OS (b) according to the proportion of IFNAR1-positive cells in pretreatment specimensBack to article page